Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Insulet Corporation - Common Stock (NQ: PODD )

283.68 +2.97 (+1.06%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Insulet Corporation - Common Stock

< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stocks That Hit 52-Week Lows On Tuesday
  On Tuesday, 99 stocks hit new 52-week lows. 
Via Benzinga
Insulet Announces Full Market Release of Omnipod® 5 Automated Insulin Delivery System in Germany
From Insulet Corporation
Via Business Wire
Morgan Stanley Maintains Equal-Weight Rating for Insulet: Here's What You Need To Know
Via Benzinga
What 8 Analyst Ratings Have To Say About Insulet
Via Benzinga
Expert Ratings for Insulet
Via Benzinga
Insulet Earnings Perspective: Return On Capital Employed
Via Benzinga
Insulet to Present at Upcoming Investor Conferences
From Insulet Corporation
Via Business Wire
Benzinga's Top Ratings Upgrades, Downgrades For August 21, 2023
Via Benzinga
NVIDIA To Rally Over 80%? Here Are 10 Other Analyst Forecasts For Monday
Credit Suisse lowered the price target for The Walt Disney Company (NYSE: DIS) from $126 to $122. Credit Suisse analyst Douglas Mitchelson maintained an Outperforn rating. Disney shares gained 0.4% to... 
Via Benzinga
Recap: Insulet Q1 Earnings
Via Benzinga
4 Analysts Have This to Say About Insulet
Via Benzinga
Analyst Expectations for Insulet's Future
Via Benzinga
JP Morgan Bullish On Insulet, Forecasts Robust Pump Market with Long Runway for Growth
J.P. 
Via Benzinga
Insulet Reports Second Quarter 2023 Revenue Increase of 32% Year-Over-Year (32% Constant Currency1)
From Insulet Corporation
Via Business Wire
Where to Invest $5,000 for the Next 20 Years
These are high-growth opportunities investors should focus on for the long haul. 
Via The Motley Fool
Just 8 S&P 500 Stocks Make The Cut In Goldman's 'Rule Of 10' Screens
This elite eight meet long-term growth criteria for sales and earnings. 
Via Investor's Business Daily
Insulet to Announce Second Quarter 2023 Financial Results on August 8, 2023
From Insulet Corporation
Via Business Wire
Goldman Sachs Reveals Winning Portfolio: 'Rule of 10' Unlocks S&P 500's Future Top Performers
Via Benzinga
Insulet Celebrates One Year of Omnipod® 5 at the American Diabetes Association 83rd Scientific Sessions
From Insulet Corporation
Via Business Wire
Insulet Announces Omnipod® 5 Automated Insulin Delivery System is Now Available in the United Kingdom
From Insulet Corporation
Via Business Wire
Medtronic's EOflow Acquisition Will Not Impact Insulet's Omnipod' Insulin Pump In Near or Medium Term: Analyst
Via Benzinga
AMD Stock, AI Play And New S&P 500 Member Lead 5 Stocks Near Buy Points
AMD and a new S&P 500 member lead this weekend's watch list. 
Via Investor's Business Daily
Insulet Reports Better-Than-Expected Q1 Earnings As Omnipod 5 Launch Gains Momentum, Lifts Guidance
  
Via Benzinga
Insulet Announces New Organizational Structure to Drive Further Growth
From Insulet Corporation
Via Business Wire
Insulet Reports First Quarter 2023 Revenue Increase of 21% Year-Over-Year (23% Constant Currency1)
From Insulet Corporation
Via Business Wire
Insulet Publishes 2022 Sustainability Report Focused on Innovating for the Future and Preserving the Environment
From Insulet Corporation
Via Business Wire
Insulet Announces FDA Clearance of Omnipod GO™, a First-of-its-Kind Basal-Only Insulin Pod, Further Simplifying Life for People with Type 2 Diabetes
From Insulet Corporation
Via Business Wire
5 S&P 500 Stocks Showing Strength As Recession Fears Rise
Medical stocks are holding up amid economic and market uncertainty. 
Via Investor's Business Daily
Insulet to Announce First Quarter 2023 Financial Results on May 4, 2023
From Insulet Corporation
Via Business Wire
CORRECTING and REPLACING Insulet Reports Full Year 2022 Revenue Increase of 19% (22% constant currency1) and Fourth Quarter 2022 Revenue Increase of 20% Year-Over-Year (24% constant currency)
From Insulet Corporation
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.